Bright expression of CD91 identifies highly activated human dendritic cells that can be expanded by defensins

Monica Cappelletti, Pietro Presicce, Francesca Calcaterra, Domenico Mavilio, Silvia Della Bella

Research output: Contribution to journalArticle

Abstract

Summary: CD91 is a scavenger receptor expressed by different immune cells and its ligands defensins have been demonstrated to contribute to immune responses against infections and tumours. We previously demonstrated that CD91 is expressed on human monocyte-derived dendritic cells (moDCs) and that human defensins stimulate in vitro the activation of these cells. In this study, we observed that CD91 is expressed at different levels on two distinct moDC subsets: CD91dim and CD91bright moDCs. Although CD91bright moDCs represented a small proportion of total moDCs, this subset showed higher levels of activation and maturation markers compared with CD91dim moDCs. The frequency of CD91bright moDCs increased by ~ 50% after in vitro stimulation with recombinant human neutrophil peptide-1 (rHNP-1) and recombinant human β defensin-1 (rHBD-1), while lipopolysaccharide (LPS) stimulation decreased it by ~ 35%. Both defensins up-regulated moDC expression of CD80, CD40, CD83 and HLA-DR, although to a lower extent compared with LPS. Notably, upon culture with rHNP-1 and rHBD-1, CD91bright moDCs maintained their higher activation/maturation status, whereas this was lost upon culture with LPS. Our findings suggest that defensins promote the differentiation into activated CD91bright DCs and may encourage the exploitation of the CD91/defensins axis as a novel therapeutic strategy to potentiate antimicrobial and anti-tumour immune response.

Original languageEnglish
Pages (from-to)661-667
Number of pages7
JournalImmunology
Volume144
Issue number4
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

Defensins
Dendritic Cells
Monocytes
Lipopolysaccharides
Scavenger Receptors
HLA-DR Antigens
Neoplasms
Ligands
Infection

Keywords

  • CD91
  • Defensins
  • Dendritic cells
  • Human neutrophil peptide-1
  • Human β defensin-1

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Bright expression of CD91 identifies highly activated human dendritic cells that can be expanded by defensins. / Cappelletti, Monica; Presicce, Pietro; Calcaterra, Francesca; Mavilio, Domenico; Della Bella, Silvia.

In: Immunology, Vol. 144, No. 4, 01.04.2015, p. 661-667.

Research output: Contribution to journalArticle

Cappelletti, Monica ; Presicce, Pietro ; Calcaterra, Francesca ; Mavilio, Domenico ; Della Bella, Silvia. / Bright expression of CD91 identifies highly activated human dendritic cells that can be expanded by defensins. In: Immunology. 2015 ; Vol. 144, No. 4. pp. 661-667.
@article{4f116d1147834580b223ae4d60f95569,
title = "Bright expression of CD91 identifies highly activated human dendritic cells that can be expanded by defensins",
abstract = "Summary: CD91 is a scavenger receptor expressed by different immune cells and its ligands defensins have been demonstrated to contribute to immune responses against infections and tumours. We previously demonstrated that CD91 is expressed on human monocyte-derived dendritic cells (moDCs) and that human defensins stimulate in vitro the activation of these cells. In this study, we observed that CD91 is expressed at different levels on two distinct moDC subsets: CD91dim and CD91bright moDCs. Although CD91bright moDCs represented a small proportion of total moDCs, this subset showed higher levels of activation and maturation markers compared with CD91dim moDCs. The frequency of CD91bright moDCs increased by ~ 50{\%} after in vitro stimulation with recombinant human neutrophil peptide-1 (rHNP-1) and recombinant human β defensin-1 (rHBD-1), while lipopolysaccharide (LPS) stimulation decreased it by ~ 35{\%}. Both defensins up-regulated moDC expression of CD80, CD40, CD83 and HLA-DR, although to a lower extent compared with LPS. Notably, upon culture with rHNP-1 and rHBD-1, CD91bright moDCs maintained their higher activation/maturation status, whereas this was lost upon culture with LPS. Our findings suggest that defensins promote the differentiation into activated CD91bright DCs and may encourage the exploitation of the CD91/defensins axis as a novel therapeutic strategy to potentiate antimicrobial and anti-tumour immune response.",
keywords = "CD91, Defensins, Dendritic cells, Human neutrophil peptide-1, Human β defensin-1",
author = "Monica Cappelletti and Pietro Presicce and Francesca Calcaterra and Domenico Mavilio and {Della Bella}, Silvia",
year = "2015",
month = "4",
day = "1",
doi = "10.1111/imm.12418",
language = "English",
volume = "144",
pages = "661--667",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Bright expression of CD91 identifies highly activated human dendritic cells that can be expanded by defensins

AU - Cappelletti, Monica

AU - Presicce, Pietro

AU - Calcaterra, Francesca

AU - Mavilio, Domenico

AU - Della Bella, Silvia

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Summary: CD91 is a scavenger receptor expressed by different immune cells and its ligands defensins have been demonstrated to contribute to immune responses against infections and tumours. We previously demonstrated that CD91 is expressed on human monocyte-derived dendritic cells (moDCs) and that human defensins stimulate in vitro the activation of these cells. In this study, we observed that CD91 is expressed at different levels on two distinct moDC subsets: CD91dim and CD91bright moDCs. Although CD91bright moDCs represented a small proportion of total moDCs, this subset showed higher levels of activation and maturation markers compared with CD91dim moDCs. The frequency of CD91bright moDCs increased by ~ 50% after in vitro stimulation with recombinant human neutrophil peptide-1 (rHNP-1) and recombinant human β defensin-1 (rHBD-1), while lipopolysaccharide (LPS) stimulation decreased it by ~ 35%. Both defensins up-regulated moDC expression of CD80, CD40, CD83 and HLA-DR, although to a lower extent compared with LPS. Notably, upon culture with rHNP-1 and rHBD-1, CD91bright moDCs maintained their higher activation/maturation status, whereas this was lost upon culture with LPS. Our findings suggest that defensins promote the differentiation into activated CD91bright DCs and may encourage the exploitation of the CD91/defensins axis as a novel therapeutic strategy to potentiate antimicrobial and anti-tumour immune response.

AB - Summary: CD91 is a scavenger receptor expressed by different immune cells and its ligands defensins have been demonstrated to contribute to immune responses against infections and tumours. We previously demonstrated that CD91 is expressed on human monocyte-derived dendritic cells (moDCs) and that human defensins stimulate in vitro the activation of these cells. In this study, we observed that CD91 is expressed at different levels on two distinct moDC subsets: CD91dim and CD91bright moDCs. Although CD91bright moDCs represented a small proportion of total moDCs, this subset showed higher levels of activation and maturation markers compared with CD91dim moDCs. The frequency of CD91bright moDCs increased by ~ 50% after in vitro stimulation with recombinant human neutrophil peptide-1 (rHNP-1) and recombinant human β defensin-1 (rHBD-1), while lipopolysaccharide (LPS) stimulation decreased it by ~ 35%. Both defensins up-regulated moDC expression of CD80, CD40, CD83 and HLA-DR, although to a lower extent compared with LPS. Notably, upon culture with rHNP-1 and rHBD-1, CD91bright moDCs maintained their higher activation/maturation status, whereas this was lost upon culture with LPS. Our findings suggest that defensins promote the differentiation into activated CD91bright DCs and may encourage the exploitation of the CD91/defensins axis as a novel therapeutic strategy to potentiate antimicrobial and anti-tumour immune response.

KW - CD91

KW - Defensins

KW - Dendritic cells

KW - Human neutrophil peptide-1

KW - Human β defensin-1

UR - http://www.scopus.com/inward/record.url?scp=84924370901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924370901&partnerID=8YFLogxK

U2 - 10.1111/imm.12418

DO - 10.1111/imm.12418

M3 - Article

AN - SCOPUS:84924370901

VL - 144

SP - 661

EP - 667

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - 4

ER -